Harmony Biosciences Holdings, Inc. (HRMY) has a consensus analyst rating of Buy, based on 13 analysts covering the stock. Of those, 10 recommend buying, 1 recommend holding, and 2 recommend selling.
The analyst consensus price target for HRMY is $46.80, representing a +59.8% upside from the current price of $29.29. Price targets range from a low of $31.00 to a high of $62.00.
